** Shares of drug developer iTeos Therapeutics ITOS.O rise 25.09% to $10.67 premarket
** Co says it plans to leverage its cash reserves to deliver near-term shareholder value as it winds down operations and explore sale of key assets as part of a strategic review
** As of last close, co's market cap was $326.48 million vs its cash balance of $624.3 million as of March 31
** Co's potential asset sale may include experimental cancer drugs and preclinical obesity program
** Earlier this month, co and GSK GSK.L stopped the development of an experimental lung cancer drug, belrestotug, after it failed to stop the disease from progressing in two studies
** Up to last close, stock up ~11% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。